In This Issue
Cancer Discov July 1 2018 8 (7) 781-783; DOI:10.1158/2159-8290.CD-ITI8-7
The FGFR1–3 inhibitor BGJ398 achieved responses with an acceptable safety profile in an expansion cohort of 67 patients with metastatic FGFR3-altered urothelial carcinoma.
In patients with KRAS-mutant lung adenocarcinoma, co-occurring alterations in STK11 conferred primary resistance to PD-1 blockade, suggesting that genomic profiling may guide selection of patients likely to respond.
BLU-667 is a potent selective RET inhibitor with activity against multiple RET mutations and fusions, and it achieved clinical responses with limited toxicity in four patients with RET-driven tumors.
High-throughput enhancer profiling identifies metastasis-associated enhancers that are activated to drive CXCR4 expression and metastatic colonization in clear cell renal cell carcinoma.
AMPK-dependent macropinocytosis of necrotic cell debris enhances the growth and survival of PTEN-deficient prostate cancer cells.
CDK6 antagonizes p53 to promote leukemia cell growth, and CDK6 loss promotes the outgrowth of p53 mutant malignant cell lines, suggesting a potential risk in therapeutic targeting of CDK6.